Publications

Patient (Pt) Preference for the Pertuzumab-Trastuzumab Fixed-Dose Combination for Subcutaneous Use (Ph Fdc Sc) in Her2-Positive Early Breast Cancer (Ebc): Primary Analysis of the Open-Label, Randomised Crossover Phrancesca Study

AuthID
P-00S-WHK

Author(s)

O'Shaughnessy, J

Sousa, S

Cruz, J

Fallowfield, L

Auvinen, P

Pulido, C

Cvetanovic, A

Wilks, S

Ribeiro, L

Burotto, M

Klingbiel, D

Messeri, D

Alexandrou, A

Trask, P

Fredriksson, J

Machackova, Z

Stamatovic, L

Document Type

Abstract

Year published

2020

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 31, Pages: S306-S307 (2)

Conference

Esmo Virtual Congress, Date: SEP 19-OCT 18, 2020, Location: ELECTR NETWORK, Sponsors: European Soc Med Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2020.08.287

Wos: WOS:000573469100165

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Patient (Pt) Preference for the Pertuzumab-Trastuzumab Fixed-Dose Combination for Subcutaneous Use (Ph Fdc Sc) in Her2-Positive Early Breast Cancer (Ebc): Primary Analysis of the Open-Label, Randomised Crossover Phrancesca Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Patient (Pt) Preference for the Pertuzumab-Trastuzumab Fixed-Dose Combination for Subcutaneous Use (Ph Fdc Sc) in Her2-Positive Early Breast Cancer (Ebc): Primary Analysis of the Open-Label, Randomised Crossover Phrancesca Study

Useful Links

Get Help